Currency in INR
| Earnings estimate | Current qtr. (Sep 2021) | Next qtr. (Dec 2021) | Current year (2022) | Next year (2023) |
|---|
| No. of analysts | 2 | 2 | 25 | 25 |
| Avg. Estimate | 14 | 14.17 | 55.77 | 62.29 |
| Low estimate | 13.3 | 13.94 | 47.7 | 49.1 |
| High estimate | 14.7 | 14.4 | 63.52 | 69.28 |
| Year ago EPS | N/A | N/A | N/A | 55.77 |
| Revenue estimate | Current qtr. (Sep 2021) | Next qtr. (Dec 2021) | Current year (2022) | Next year (2023) |
|---|
| No. of analysts | 3 | 3 | 26 | 25 |
| Avg. Estimate | 61.7B | 63.62B | 250.11B | 271.28B |
| Low estimate | 59.2B | 62.27B | 234.74B | 242.8B |
| High estimate | 64.52B | 65.38B | 268.4B | 298.66B |
| Year ago sales | N/A | N/A | N/A | 250.11B |
| Sales growth (year/est) | N/A | N/A | N/A | 8.50% |
| Earnings history | Invalid Date | Invalid Date | Invalid Date | 30/06/2021 |
|---|
| Est. EPS | N/A | N/A | N/A | 14.53 |
| Actual EPS | N/A | N/A | N/A | 13.14 |
| Difference | N/A | N/A | N/A | -1.39 |
| Surprise % | N/A | N/A | N/A | -9.60% |
| EPS trend | Current qtr. (Sep 2021) | Next qtr. (Dec 2021) | Current year (2022) | Next year (2023) |
|---|
| Current estimate | 14 | 14.17 | 55.77 | 62.29 |
| 7 days ago | 0 | 0 | 0 | 0 |
| 30 days ago | 0 | 0 | 0 | 0 |
| 60 days ago | 0 | 0 | 0 | 0 |
| 90 days ago | 0 | 0 | 0 | 0 |
| EPS revisions | Current qtr. (Sep 2021) | Next qtr. (Dec 2021) | Current year (2022) | Next year (2023) |
|---|
| Up last 7 days | N/A | N/A | 1 | N/A |
| Up last 30 days | N/A | N/A | 1 | N/A |
| Down last 7 days | N/A | N/A | N/A | N/A |
| Down last 30 days | N/A | N/A | N/A | 1 |
| Growth estimates | AUROPHARMA.NS | Industry | Sector(s) | S&P 500 |
|---|
| Current qtr. | N/A | N/A | N/A | N/A |
| Next qtr. | N/A | N/A | N/A | N/A |
| Current year | N/A | N/A | N/A | N/A |
| Next year | 11.70% | N/A | N/A | N/A |
| Next 5 years (per annum) | 11.30% | N/A | N/A | N/A |
| Past 5 years (per annum) | 8.19% | N/A | N/A | N/A |
